A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Lilly

Status and phase: Enrolling; Phase 2

Conditions: Plaque Psoriasis

Treatments: Drug: Placebo; Drug: LY3972406

Study type: Interventional

Funder types: Industry

Identifiers

NCT06176768

2023-504485-39-00 (Other Identifier)

J4H-MC-FVAA (Other Identifier)

18692

Details and patient eligibility

About

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Enrollment: 75 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
• Have venous access sufficient to allow for blood sampling
• Are able to swallow oral medication
• Agree to skin biopsies

Exclusion criteria

• Have any other skin conditions, excluding plaque psoriasis
• Have a current or recent acute, active infection
• Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
• Are lactating or breastfeeding women

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

75 participants in 3 patient groups, including a placebo group

LY3972406 Dose 1

Experimental group

Description:

Participants will receive an oral dose of LY3972406

Treatment:

Drug: LY3972406

LY3972406 Dose 2

Experimental group

Description:

Participants will receive an oral dose of LY3972406

Treatment:

Drug: LY3972406

Placebo

Placebo Comparator group

Description:

Participants will receive placebo.

Treatment:

Drug: Placebo